Why the study?
Does pravastatin 40 mg reduce all-cause mortality compared to usual care in hypertensive patients aged 55 years or older?
Does pravastatin 40 mg reduce all-cause mortality compared to usual care in hypertensive patients aged 55 years or older?
The ALLHAT-LLT trial demonstrated that open-label pravastatin 40 mg did not reduce all-cause mortality compared to usual care in hypertensive patients, despite effectively lowering LDL-C.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Lipid Lowering Trial (ALLHAT-LLT),1 published in this issue of THE JOURNAL, is the second-largest lipid-lowering trial yet reported. This randomized trial, a subset of the larger ALLHAT hypertension study,2 followed up 10 355 patients (49% women) who had hypertension and were 55 years or older for a mean of 4.8 years. Patients were randomly assigned to receive 40 mg of pravastatin (open label) vs usual care in 513 clinical centers, the majority of which were community-based. These centers were a subset of the 623 centers that treated patients for the larger (N = 33 357) ALLHAT hypertension study.2 Despite a 28% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline in the pravastatin treatment group, the trial failed to show a benefit in either the primary outcome (all-cause mortality) or the key secondary outcome (combined nonfatal myocardial infarction and . . .
No takes yet. Share an insight, caveat, or question.
Richard C. Pasternak (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: